Review



beta cells cd64t  (TaKaRa)


Bioz Verified Symbol TaKaRa is a verified supplier
Bioz Manufacturer Symbol TaKaRa manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    TaKaRa beta cells cd64t
    a , b , Human thyroid epiCs TPO and epiCs <t>TPO,CD64t</t> were challenged in impedance NK cell ADCC ( a ) and CDC ( b ) assays with different concentrations of an anti-TPO IgG1 antibody (mean ± s.d.; three independent replicates per group and timepoint). c – e , Human thyroid epiCs TPO and epiCs TPO,CD64t were incubated with serum from Hashimoto’s patients 1 ( c ), 2 ( d ) and 3 ( e ) in impedance CDC assays (mean ± s.d.; three independent replicates per group and timepoint). ULN, upper limit of normal. f , 5 × 10 4 human thyroid epiCs TPO or epiCs TPO,CD64t were injected subcutaneously into NSG mice with 10 6 human NK cells. Both groups received three subcutaneous doses of anti-TPO IgG1 1 mg on days 0, 1 and 2. g , h , BLI signals of thyroid epiCs TPO ( g ) and epiCs TPO,CD64t ( h ) were followed (all individual mice were plotted, and BLI pictures of one representative mouse per group are shown). s.c., subcutaneous.
    Beta Cells Cd64t, supplied by TaKaRa, used in various techniques. Bioz Stars score: 93/100, based on 7 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/beta cells cd64t/product/TaKaRa
    Average 93 stars, based on 7 article reviews
    beta cells cd64t - by Bioz Stars, 2026-04
    93/100 stars

    Images

    1) Product Images from "Protection of cell therapeutics from antibody-mediated killing by CD64 overexpression"

    Article Title: Protection of cell therapeutics from antibody-mediated killing by CD64 overexpression

    Journal: Nature Biotechnology

    doi: 10.1038/s41587-022-01540-7

    a , b , Human thyroid epiCs TPO and epiCs TPO,CD64t were challenged in impedance NK cell ADCC ( a ) and CDC ( b ) assays with different concentrations of an anti-TPO IgG1 antibody (mean ± s.d.; three independent replicates per group and timepoint). c – e , Human thyroid epiCs TPO and epiCs TPO,CD64t were incubated with serum from Hashimoto’s patients 1 ( c ), 2 ( d ) and 3 ( e ) in impedance CDC assays (mean ± s.d.; three independent replicates per group and timepoint). ULN, upper limit of normal. f , 5 × 10 4 human thyroid epiCs TPO or epiCs TPO,CD64t were injected subcutaneously into NSG mice with 10 6 human NK cells. Both groups received three subcutaneous doses of anti-TPO IgG1 1 mg on days 0, 1 and 2. g , h , BLI signals of thyroid epiCs TPO ( g ) and epiCs TPO,CD64t ( h ) were followed (all individual mice were plotted, and BLI pictures of one representative mouse per group are shown). s.c., subcutaneous.
    Figure Legend Snippet: a , b , Human thyroid epiCs TPO and epiCs TPO,CD64t were challenged in impedance NK cell ADCC ( a ) and CDC ( b ) assays with different concentrations of an anti-TPO IgG1 antibody (mean ± s.d.; three independent replicates per group and timepoint). c – e , Human thyroid epiCs TPO and epiCs TPO,CD64t were incubated with serum from Hashimoto’s patients 1 ( c ), 2 ( d ) and 3 ( e ) in impedance CDC assays (mean ± s.d.; three independent replicates per group and timepoint). ULN, upper limit of normal. f , 5 × 10 4 human thyroid epiCs TPO or epiCs TPO,CD64t were injected subcutaneously into NSG mice with 10 6 human NK cells. Both groups received three subcutaneous doses of anti-TPO IgG1 1 mg on days 0, 1 and 2. g , h , BLI signals of thyroid epiCs TPO ( g ) and epiCs TPO,CD64t ( h ) were followed (all individual mice were plotted, and BLI pictures of one representative mouse per group are shown). s.c., subcutaneous.

    Techniques Used: Incubation, Injection

    a , Flow cytometry histograms for anti-CD19 scFv and CD64t expression on human CAR T and CAR T CD64t cells (representative graphs of two independent experiments). b , Flow cytometry histograms for the binding of free IgG1 F c (anti-TPO IgG1; representative graph of two independent experiments). c , The kinetics of Nalm6 target cell killing by T cells, CAR T cells and CAR T CD64t cells is expressed as hours that it takes for the cell index to drop from 1 to 0.5. Different T cell-to-Nalm6 ratios are shown (mean ± s.d.; three independent replicates per group and timepoint). d , The kinetics of Nalm6 target cell killing by CAR T CD64t in the presence and absence of 1 μg ml −1 of anti-CD52 is expressed as hours that it takes for the cell index to drop from 1 to 0.5. Different CAR T cell-to-Nalm6 ratios are shown (mean ± s.d.; three independent replicates per group and timepoint). e , f , Human CAR T and CAR T CD64t cells were challenged in impedance NK cell ADCC ( e ) and CDC ( f ) assays with antibodies against HLA (HLA-A2), non-HLA (CD52 and CD3), rhesus blood type antigen D (Rh(D)) and the CAR (anti-CD19 scFv) at 1 μg ml −1 (mean ± s.d.; three independent replicates per group and timepoint).
    Figure Legend Snippet: a , Flow cytometry histograms for anti-CD19 scFv and CD64t expression on human CAR T and CAR T CD64t cells (representative graphs of two independent experiments). b , Flow cytometry histograms for the binding of free IgG1 F c (anti-TPO IgG1; representative graph of two independent experiments). c , The kinetics of Nalm6 target cell killing by T cells, CAR T cells and CAR T CD64t cells is expressed as hours that it takes for the cell index to drop from 1 to 0.5. Different T cell-to-Nalm6 ratios are shown (mean ± s.d.; three independent replicates per group and timepoint). d , The kinetics of Nalm6 target cell killing by CAR T CD64t in the presence and absence of 1 μg ml −1 of anti-CD52 is expressed as hours that it takes for the cell index to drop from 1 to 0.5. Different CAR T cell-to-Nalm6 ratios are shown (mean ± s.d.; three independent replicates per group and timepoint). e , f , Human CAR T and CAR T CD64t cells were challenged in impedance NK cell ADCC ( e ) and CDC ( f ) assays with antibodies against HLA (HLA-A2), non-HLA (CD52 and CD3), rhesus blood type antigen D (Rh(D)) and the CAR (anti-CD19 scFv) at 1 μg ml −1 (mean ± s.d.; three independent replicates per group and timepoint).

    Techniques Used: Flow Cytometry, Expressing, Binding Assay



    Similar Products

    beta cells cd64t  (TaKaRa)
    93
    TaKaRa beta cells cd64t
    a , b , Human thyroid epiCs TPO and epiCs <t>TPO,CD64t</t> were challenged in impedance NK cell ADCC ( a ) and CDC ( b ) assays with different concentrations of an anti-TPO IgG1 antibody (mean ± s.d.; three independent replicates per group and timepoint). c – e , Human thyroid epiCs TPO and epiCs TPO,CD64t were incubated with serum from Hashimoto’s patients 1 ( c ), 2 ( d ) and 3 ( e ) in impedance CDC assays (mean ± s.d.; three independent replicates per group and timepoint). ULN, upper limit of normal. f , 5 × 10 4 human thyroid epiCs TPO or epiCs TPO,CD64t were injected subcutaneously into NSG mice with 10 6 human NK cells. Both groups received three subcutaneous doses of anti-TPO IgG1 1 mg on days 0, 1 and 2. g , h , BLI signals of thyroid epiCs TPO ( g ) and epiCs TPO,CD64t ( h ) were followed (all individual mice were plotted, and BLI pictures of one representative mouse per group are shown). s.c., subcutaneous.
    Beta Cells Cd64t, supplied by TaKaRa, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/beta cells cd64t/product/TaKaRa
    Average 93 stars, based on 1 article reviews
    beta cells cd64t - by Bioz Stars, 2026-04
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    a , b , Human thyroid epiCs TPO and epiCs TPO,CD64t were challenged in impedance NK cell ADCC ( a ) and CDC ( b ) assays with different concentrations of an anti-TPO IgG1 antibody (mean ± s.d.; three independent replicates per group and timepoint). c – e , Human thyroid epiCs TPO and epiCs TPO,CD64t were incubated with serum from Hashimoto’s patients 1 ( c ), 2 ( d ) and 3 ( e ) in impedance CDC assays (mean ± s.d.; three independent replicates per group and timepoint). ULN, upper limit of normal. f , 5 × 10 4 human thyroid epiCs TPO or epiCs TPO,CD64t were injected subcutaneously into NSG mice with 10 6 human NK cells. Both groups received three subcutaneous doses of anti-TPO IgG1 1 mg on days 0, 1 and 2. g , h , BLI signals of thyroid epiCs TPO ( g ) and epiCs TPO,CD64t ( h ) were followed (all individual mice were plotted, and BLI pictures of one representative mouse per group are shown). s.c., subcutaneous.

    Journal: Nature Biotechnology

    Article Title: Protection of cell therapeutics from antibody-mediated killing by CD64 overexpression

    doi: 10.1038/s41587-022-01540-7

    Figure Lengend Snippet: a , b , Human thyroid epiCs TPO and epiCs TPO,CD64t were challenged in impedance NK cell ADCC ( a ) and CDC ( b ) assays with different concentrations of an anti-TPO IgG1 antibody (mean ± s.d.; three independent replicates per group and timepoint). c – e , Human thyroid epiCs TPO and epiCs TPO,CD64t were incubated with serum from Hashimoto’s patients 1 ( c ), 2 ( d ) and 3 ( e ) in impedance CDC assays (mean ± s.d.; three independent replicates per group and timepoint). ULN, upper limit of normal. f , 5 × 10 4 human thyroid epiCs TPO or epiCs TPO,CD64t were injected subcutaneously into NSG mice with 10 6 human NK cells. Both groups received three subcutaneous doses of anti-TPO IgG1 1 mg on days 0, 1 and 2. g , h , BLI signals of thyroid epiCs TPO ( g ) and epiCs TPO,CD64t ( h ) were followed (all individual mice were plotted, and BLI pictures of one representative mouse per group are shown). s.c., subcutaneous.

    Article Snippet: A 24-well plate was coated with gelatin, and 5 × 10 4 iPSC-derived beta cells and beta cells CD64t (Y10108, Takara Bio) per well were seeded in 500 μl of Cellartis hiPS beta cell media and incubated for 24 hours at 37 °C in 5% CO 2 .

    Techniques: Incubation, Injection

    a , Flow cytometry histograms for anti-CD19 scFv and CD64t expression on human CAR T and CAR T CD64t cells (representative graphs of two independent experiments). b , Flow cytometry histograms for the binding of free IgG1 F c (anti-TPO IgG1; representative graph of two independent experiments). c , The kinetics of Nalm6 target cell killing by T cells, CAR T cells and CAR T CD64t cells is expressed as hours that it takes for the cell index to drop from 1 to 0.5. Different T cell-to-Nalm6 ratios are shown (mean ± s.d.; three independent replicates per group and timepoint). d , The kinetics of Nalm6 target cell killing by CAR T CD64t in the presence and absence of 1 μg ml −1 of anti-CD52 is expressed as hours that it takes for the cell index to drop from 1 to 0.5. Different CAR T cell-to-Nalm6 ratios are shown (mean ± s.d.; three independent replicates per group and timepoint). e , f , Human CAR T and CAR T CD64t cells were challenged in impedance NK cell ADCC ( e ) and CDC ( f ) assays with antibodies against HLA (HLA-A2), non-HLA (CD52 and CD3), rhesus blood type antigen D (Rh(D)) and the CAR (anti-CD19 scFv) at 1 μg ml −1 (mean ± s.d.; three independent replicates per group and timepoint).

    Journal: Nature Biotechnology

    Article Title: Protection of cell therapeutics from antibody-mediated killing by CD64 overexpression

    doi: 10.1038/s41587-022-01540-7

    Figure Lengend Snippet: a , Flow cytometry histograms for anti-CD19 scFv and CD64t expression on human CAR T and CAR T CD64t cells (representative graphs of two independent experiments). b , Flow cytometry histograms for the binding of free IgG1 F c (anti-TPO IgG1; representative graph of two independent experiments). c , The kinetics of Nalm6 target cell killing by T cells, CAR T cells and CAR T CD64t cells is expressed as hours that it takes for the cell index to drop from 1 to 0.5. Different T cell-to-Nalm6 ratios are shown (mean ± s.d.; three independent replicates per group and timepoint). d , The kinetics of Nalm6 target cell killing by CAR T CD64t in the presence and absence of 1 μg ml −1 of anti-CD52 is expressed as hours that it takes for the cell index to drop from 1 to 0.5. Different CAR T cell-to-Nalm6 ratios are shown (mean ± s.d.; three independent replicates per group and timepoint). e , f , Human CAR T and CAR T CD64t cells were challenged in impedance NK cell ADCC ( e ) and CDC ( f ) assays with antibodies against HLA (HLA-A2), non-HLA (CD52 and CD3), rhesus blood type antigen D (Rh(D)) and the CAR (anti-CD19 scFv) at 1 μg ml −1 (mean ± s.d.; three independent replicates per group and timepoint).

    Article Snippet: A 24-well plate was coated with gelatin, and 5 × 10 4 iPSC-derived beta cells and beta cells CD64t (Y10108, Takara Bio) per well were seeded in 500 μl of Cellartis hiPS beta cell media and incubated for 24 hours at 37 °C in 5% CO 2 .

    Techniques: Flow Cytometry, Expressing, Binding Assay